非选择性β受体阻滞剂在肝硬化个体中应用的临床意义  

Clinical significance of non-selectiveβreceptor blockers in liver cirrhosis patients

作　　者：唐英 张倩[1] 柳思琪 贾胜男[1] 张传辉[1] 杨岚岚[1] Tang Ying;Zhang Qian;Liu Siqi;Jia Shengnan;Zhang Chuanhui;Yang Lanlan(Department of Hepatopancreatobiliary Medicine,the Second Hospital of Jilin University,Changchun 1300001 China)

机构地区：[1]吉林大学第二医院肝胆胰内科,长春130000

出　　处：《中国医药》2021年第11期1747-1750,共4页China Medicine

基　　金：吉林省自然科学基金(20200201482JC)。

摘　　要：β受体阻滞剂在失代偿期肝硬化中的临床应用已有多年历史,尤其是在缓解肝硬化门静脉高压及预防曲张静脉出血方面被充分肯定。然而,近期有新的研究表明非选择性β受体阻滞剂在治疗失代偿期肝硬化过程中可能会产生其他不利影响,例如在降低门静脉压的同时,血流动力学的改变造成门静脉血栓形成,并且那些合并顽固性腹腔积液和/或肾功能衰竭的患者似乎也并不适合应用该类药物。这就提示了针对肝硬化特定的病理生理阶段需要将非选择性β受体阻滞剂治疗方案个体化。本文概述了非选择性β受体阻滞剂在肝硬化中应用的利弊,旨在为患者使用非选择性β受体阻滞剂提供建议。βreceptor blockers have been used in decompensated liver cirrhosis for many years.It is fully affirmed,especially in relieving liver cirrhosis portal hypertension and preventing variceal bleeding.However,recent studies have shown that non-selectiveβreceptor blockers may have other adverse effects on the treatment of decompensated liver cirrhosis,such as portal vein thrombosis caused by hemodynamic changes while reducing portal vein pressure,and it does not seem to be suitable for patients with refractory ascites and/or renal failure.This suggests that it is necessary to individualize the treatment of non-selectiveβreceptor blockers for the specific pathophysiological stage of liver cirrhosis.This paper reviews the advantages and disadvantages of non-selectiveβreceptor blockers in the treatment of decompensated liver cirrhosis,in order to provide practical suggestions for patients how to use that.

关 键 词：肝硬化 非选择性Β受体阻滞剂 门静脉高压 肝癌 

分 类 号：R657.3[医药卫生—外科学]